abemaciclib
eli lilly
['breast', 'abema', 'abemaciclib', 'bcsm']
factors associated with early discontinuation of adjuvant abemaciclib for hormone receptor positive, her2-negative, node-positive high-risk early breast cancer inform future treatment monitoring. #bcsm #asco22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.